Financing for the R&D has been secured in seed funding in March 2015 from the ZKB, the Swiss Innovation Promotion Agency KTI/CTI, and other valuable grants. These funds will be spent to optimize the manufacturing, complete the proof of efficacy and safety of VS-01 and set-up the operational activities.
Versantis receives the support of CHF 320'000.- from The Gebert Ruef Stiftung.
Versantis sincerely acknowledges the Gebert Ruef Stiftung for its significant financial support that will be instrumental for the translation of VS-01 from an academic prototype to a product ready to undergo preclinical regulatory studies and potentially attract investors.
The charter of Gebert Rüf Stiftung founded in 1997 states the purpose article as «promoting Switzerland as a place to live and do business». The mission statement of the foundation provides support for new approaches and selected junior scientists in the so-called valley of death. In line with the support criteria, a project must be impact-oriented and of a high caliber if it is to be eligible. Gebert Rüf Stiftung is not an operating foundation that exclusively maintains its own projects, but is above all a grant-making foundation which actively shapes and enables.